



12 & 13 January 2015

PARIS - Palais des Congrès

**International Conference on the Management
of Patients with Viral Hepatitis**

Organised by Pr Patrick Marcellin

Organising Committee:

Pr Tarik Asselah,

Dr Nathalie Boyer, Dr Emilie Estrabaud,

Dr Michelle Martinot-Peignoux, Dr Monelle Muntlak

Hôpital Beaujon, APHP - UMR 1149 Inserm, CRI - Université Paris-Diderot

www.aphc.info

HEPATITIS C

08.30 Introduction: Treatment of hepatitis C: towards the eradication?

Patrick Marcellin (France)

08.40 - 09.00 State of the art lecture

Chairman: Tarik Asselah (France)

- Treatment of hepatitis C today and tomorrow

Antonio Craxi (Italy)

09.00 - 10.00 How to optimize current therapy of G1 patients

Chairmen: Nezam Afdhal (USA) and Stanislas Pol (France)

- 09.00 ■ PEG IFN based therapy with 2nd wave DAAs

Donald Jensen (USA)

- 09.15 ■ Shortened therapy with IFN-based therapy

Thomas Berg (Germany)

- 09.30 ■ Predictors of response to IFN-based therapy

Lawrence Serfaty (France)

- 09:45 ■ Round table discussion

10.20 - 11.20 How to optimize current therapy of non G1 patients

Chairmen: Jake Liang (USA) and Stefan Zeuzem (Germany)

10.20 ■ Genotype 2, what's new?

Marc Bourlière (France)

10.35 ■ Why genotype 3 is difficult to cure?

Graham Foster (UK)

10.50 ■ Genotype 4, finally cured?

Imam Waked (Egypt)

11.05 ■ Round table discussion

11.20 - 12.30 How to improve access to therapy? Around the World table *Patrick Marcellin (France)*

Chairmen: Massimo Colombo (Italy), Michael Fried (USA)

Speakers: Victor De Ledinghen (France), Gamal Esmat (Egypt), Rafael Esteban (Spain), Robert Flisiak (Poland), Vasily Isakov (Russia), Michael Manns (Germany), Raymundo Parana (Brazil)

Room 253

1. The long term impact of treatment on the outcome of liver disease

*Jia-Horng Kao (Taiwan),
Nurdan Tozun (Turkey)*

Room 241

2. First line therapy of hepatitis B: interferon or analogues?

*Rafael Esteban (Spain),
Cihan Yurdaydin (Turkey)*

Room 242 B

3. Clinical applications of HBsAg quantification

*Philippe Halfon (France),
Michelle Martinot-Peignoux (France),
Philippe Sogni (France)*

Room 242 A

4. Staging of fibrosis: liver biopsy or indirect markers?

*Pierre Bedossa (France),
Victor De Ledinghen (France)*

Room 252 B

5. Treatment of HCV cirrhosis and transplanted patients

*Rajiv Jalan (UK),
Didier Samuel (France),
Dominique Valla (France)*

Room 251

6. HIV-HCV coinfections

*Juergen Rockstroh (Germany),
Mark Sulkowski (USA)*

Room 252 A

7. Interferon ou analogue ? (French speaking lunch workshop)

*Denis Ouzan (France),
Christian Trépo (France),
Jean-Pierre Zarski (France)*

Room 243

8. Faut-il traiter les immunotolérants et les porteurs inactifs ? (French speaking lunch workshop)

*Mustapha Benazzouz (Morocco),
Nathalie Boyer (France),
Jean-François Cadranel (France),
Adriana Popescu (Romania)*

14.30 - 15.35 Special populations

Chairs: Maria Buti (Spain) and François Durand (France)

14:30 ■ Patients with comorbidities

Savino Bruno (Italy)

14:45 ■ DAAs and transplant patients

Didier Samuel (France)

15:00 ■ HIV co-infected patients

Juergen Rockstroh (Germany)

15:15 ■ Round table discussion

16.00 - 16.50 New therapeutic strategies

Chairmen: Ira Jacobson (USA) and Michael Manns (Germany)

16.00 ■ INF-free therapy in naïve patients

Tarik Asselah (France)

16.15 ■ INF-free therapy in experienced patients

David Nelson (USA)

16.30 ■ Round table discussion

16.50 - 17.25 Controversy: Cure of HCV-related liver disease?

Chairman: Eugene Schiff (USA)

16.50 ■ No: Mitchell Shiffman (USA)

17.00 ■ Yes: Yves Benhamou (France)

17:10 ■ Discussion

17.25 - 17.40 Hepatitis C: A public health priority

Bernard Kouchner (France)